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Revision of the fourth edition of the World Health Organisation (WHO) Classifi-
cation of Haematopoietic and Lymphatic Tissues, which was published in 2017, in-
troduced important changes updating the biology, pathology, genetics, and clinical 
presentation of aggressive B-cell lymphomas. High grade B-cell lymphomas (HG-
BLs) replaced B-cell lymphoma, unclassifiable, with features intermediate between 
diffuse large B-cell lymphoma and Burkitt lymphoma, the new provisional entity 
Burkitt-like lymphoma with 11q aberration was identified, and some categories 
were upgraded, e.g. EBV-positive diffuse large B-cell lymphoma, not otherwise 
specified. Still the histopathological diagnostics is based on morphology and im-
munoprofile, but to define the HGBLs evaluation of MYC, BCL2, and BCL6 gene 
statuses is required. According to the presented WHO criteria, in the comprehen-
sive histopathological diagnostics of aggressive B-cell lymphomas a highly special-
ised diagnostic team including a pathologist, a molecular biologist, a geneticist, 
a haematologist, and immunophenotyping technicians is needed. 
Key words: aggressive B-cell lymphomas, high grade B-cell lymphomas, Burkitt-
like lymphoma,11q aberration.
Doi: httpS://Doi.orG/10.5114/pJp.2018.75332 pol J pAthol 2018; 69 (1): 1-19
Introduction
Aggressive lymphomas from mature B cells are 
a heterogeneous group of diseases that differ in bi-
ological, pathological, and clinical features. The 
World Health Organisation (WHO) classification 
updated at the end of 2017 distinguishes 18 enti-
ties (Table I) with distinct clinical, pathological, and 
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genetic features [1]. Some types of aggressive B-cell 
lymphomas are relatively frequent, i.e. diffuse large 
B-cell lymphoma, not otherwise specified (DLBCL, 
NOS) which represents 25-35% non-Hodgkin’s lym-
phomas depending on the population; others occur 
rarely and refer to specific groups of patients. Prog-
nosis and response to therapy are different in each 
clinical-pathological unit. Although currently used 
treatment regimens are effective in the majority of 
patients, about 30% of patients develop progression 
to incurable disease [1, 2]. The results of genetic and 
molecular research conducted in recent years allow 
a better understanding of the mechanisms underly-
ing the clinical and biological diversity of these tu-
mours and provide valuable information about new 
therapeutic options, and at the same time allow 
improvement of diagnostic criteria. The aim of this 
study is to present practical diagnostic recommenda-
tions necessary for the correct diagnosis of aggressive 
B-cell lymphomas. The novelty concerning the three 
aggressive B-cell lymphomas has been discussed in 
detail: DLBCL, NOS, high-grade B-cell lymphomas 
(HGBLs), and Burkitt lymphoma/Burkitt-like lym-
phoma with 11q aberration (BL/BLL,11q); for the 
remaining units, the most important features regard-
ing clinical and pathological presentation as well as 
genetic changes are highlighted [1, 2]. Moreover, 
general rules for preservation of biological material 
and tips on supporting diagnostic techniques (immu-
nohistochemistry, flow cytometry, genetics) are given.
Preservation of biological material
Various materials are evaluated in the diagnosis 
of lymphoid tumours. Samples most often originate 
from the main structures of the lymphatic system, 
which include lymph nodes, spleen and thymus, 
Waldeyer’s ring (lymphatic tissue band surrounding 
the oral throat with palatal tonsils, and lingual and 
pharyngeal tonsils), appendix, and Peyer’s patches 
in the ileum. Other areas containing lymphatic tis-
sue concern: bone marrow, mediastinum, liver, skin, 
pleura and gonads. Patients admitted with suspicion 
of lymphoma for pathological diagnosis require bio-
logical material protection also for molecular, and/
or cytogenetic tests. Therefore, it is necessary to 
provide a standard operating procedure for material 
processing, including the following major steps: 
 – tissue obtained for testing should be fresh and pro-
cessed according to type of material; entirely ex-
cised lymph nodes should be cut into at least 5-mm 
thick slices along the long axis to ensure optimal 
penetration of a fixative;
 – description of fresh material should include the 
size, colour, texture, and the presence or absence 
of macroscopically visible haemorrhages, necrosis 
fields, or nodular architecture;
 – touch imprint cytological slides are made from 
freshly cut material surface and are fixed in alcohol 
or dried in the air;
 – for cytogenetic tests (karyotype) a fresh tissue sam-
ple or viable cells from fine-needle aspiration biopsy 
(FNAB) should be collected into a sterile container 
with cell culture medium and antibiotics, always 
considering the requirements of the laboratory per-
forming the test;
 – immunophenotyping by flow cytometry (FCM) 
requires protection of a fresh tissue sample or vi-
able cells from FNAB in an appropriate transport 
medium (e.g. RPMI-1640), always considering the 
requirements of the laboratory performing the test;
 – always indicate the type of fixative used and if pos-
sible determine the estimated time from tissue col-
Table I. Aggressive, mature B-cell lymphomas according 
the World Health Organisation’s 2017 classification
aggRessive, matuRe B-Cell lymphomas
Diffuse large B-cell lymphoma, not otherwise specified
  Germinal centre B-cell type
  Activated B-cell type
T-cell/histiocyte-rich large B-cell lymphoma
 Diffuse large B-cell lymphoma, topographic site related
  Primary mediastinal (thymic) large B-cell lymphoma
   Primary diffuse large B-cell lymphoma of the central 
nervous system 
   Primary cutaneous diffuse large B-cell lymphoma, leg 
type
  Intravascular large B-cell lymphoma
Diffuse large B-cell lymphoma, EBV related
  EBV-positive diffuse large B-cell lymphoma, NOS
   Diffuse large B-cell lymphoma associated with 
chronic inflammation
  Lymphomatoid granulomatosis
Large B-cell lymphoma with terminal B-cell 
differentiation
  Plasmablastic lymphoma
  ALK-positive large B-cell lymphoma
  Primary effusion lymphoma
  HHV8-positive diffuse large B-cell lymphoma, NOS#
Burkitt lymphoma
  Burkitt-like lymphoma with 11q aberrations#
High grade B-cell lymphoma
   High-grade B-cell lymphoma, with MYC and BCL2 
and/or BCL6 rearrangements
  High-grade B-cell lymphoma, NOS
Mantle cell lymphoma
  Blastoid or pleomorphic variant
B-cell lymphoma, unclassifiable, with features 
intermediated between diffuse large B-cell lymphoma 
and classic Hodgkin’s lymphoma
# provisional entities 
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lection to fixation, because this is important for the 
recovery of RNA and phosphorylated proteins;
 – for histopathological examination it is recommend-
ed to use a fixative based on 10% buffered formal-
dehyde (so-called formalin); most suitable for addi-
tional studies such as immunohistochemistry and 
fluorescence in situ hybridisation (FISH); to avoid 
dilution and formalin buffering problems the use 
of commercially available ready-to-use (RTU) solu-
tions is strongly advised;
 – to ensure optimal antibody reactivity preservation 
(for immunohistochemistry) extension of fixation 
time (over 24 hours for small tissue sections fixated 
in formalin) should be avoided;
 – if the size/volume of biological material and infra-
structure of the diagnostic centre allow, some sam-
ples should be biobanked through deep freezing 
(short-term storage in –80°C freezers, long-term 
storage in liquid nitrogen at –170°C). The freez-
ing technique should be complementary to further 
material processing methodology; the most popu-
lar techniques are tumour snap frozen sections or 
tumour viable cell freezing.
General remarks on pathological 
diagnostics of aggressive B-cell lymphoma:
 – histopathological examination sustains a gold stan-
dard in diagnostics; however, in most cases precise 
determination of lymphoma type requires at least 
one additional method including immunopheno-
typing, and molecular and/or cytogenetic tests [4, 
5, 6, 7, 8, 9, 10]; in cases where material is inad-
equate or insufficient for diagnostic purposes, the 
clinician should receive feedback and justify the 
above condition;
 – in certain circumstances, when a lymph node is not 
easily accessible for surgical biopsy and in patients 
requiring immediate treatment, FNAB biopsy in 
conjunction with FCM, karyotype, FISH for major 
translocation, PCR for IGH, and TCR gene rear-
rangement may be sufficient for diagnosis;
 – haematopatholgy consultation should include re-
view of all slides with at least one paraffin block 
representative of the tumour. Re-biopsy is recom-
mended if material is non-diagnostic;
 – immunophenotyping can be performed by im-
munohistochemistry or flow cytometry [8]; each 
method has its own advantages and disadvantag-
es. Flow cytometry is fast (hours) and quantita-
tive method with evaluation of multiple antigens 
simultaneously. Antigen detection, however, does 
not allow to correlate with tumour architecture and 
its cytological features. Immunohistochemistry re-
quires hours, sometimes days, and the quantitative 
assessment is subjective, but its most important 
feature is the possibility of correlation of reaction 
with architecture and tumour cytology. Moreover, 
not all antibodies are available for immunohisto-
chemical assessment, especially for fixed tissues, 
but the advantage of this method is the possibility 
of using it in the archival materials embedded in 
paraffin. Both techniques can be used in the lym-
phomas diagnostics and are a source of clinically 
relevant information (e.g. identification of mol-
ecules necessary for the use of targeted therapies 
such as CD20); 
 – the importance of molecular research in lymphoid 
malignancies is constantly growing and allows the 
determination of clonality and the origin of neo-
plastic cells. In specific entities, these tests are nec-
essary to make a definitive diagnosis i.e., Burkitt 
lymphoma, Burkitt-like lymphoma, or high-grade 
B-cell lymphoma with MYC and BCL2 and/or 
BCL6 rearrangements; 
 – for an interpretation of immunohistochemical reac-
tions a descriptive semi-quantitative scale is adopt-
ed: (+) positive reaction, (+/–) partially positive 
reaction, (–/+) positive reaction in a few, (–) nega-
tive reaction in the majority of cells; the percentage 
of positive cells for each staining may be presented 
in square brackets;
 – panB panel includes antibodies: CD19, CD20, 
CD22, CD79a, PAX5;
 – typical DLBCL immunophenotype includes: 
CD45(+), CD20(+), CD3(–) Ki-67 > 40% posi-
tive cell nuclei;
 – panel of IHC antibodies to establish DLBCL diag-
nosis and GCB vs. non-GCB origin: CD20, CD3, 
CD5, CD10, BCL2, BCL6, Ki-67, IRF4/MUM1, 
MYC with or without cell surface analysis by flow 
cytometry: k/l, CD45, CD3, CD5, CD19, CD10, 
CD20, CD71;
 – additional IHC studies to establish lymphoma sub-
type: Cyclin D1, PAX5, CD30, CD15, CD138, 
CD38, Epstein Barr virus (EBV) in situ hybridi-
sation (ISH), EBV/LMP1, ALK, HHV8, SOX11, 
CD23, BOB1, OCT2, CD56, k/l, EMA;
 – the following cutoff points are recommended accord-
ing to WHO classification: BCL2 ≥ 50% strong pos-
itive cells, MYC ≥ 40% strong positive cell nuclei, 
for CD10, BCL6, IRF4/MUM1 ≥ 30% positive cells/
nuclei. The importance of choosing an appropriate 
antibody clone, especially among those that show re-
action liability (i.e. BCL2, CD10, MYC), is highlight-
ed. For routine pathological diagnostics only certified 
antibodies (in vitro diagnostics, IVD) simultaneously 
with positive and negative controls are advised; 
 – presence of EBV virus should be confirmed by in-
tra-tissue hybridisation (EBER-ISH); it is a supe-
rior technique to immunohistochemistry (LMP1) 
(Fig. 1);
 – karyotype and/or FISH for MYC, BCL2, BCL6 re-
arrangements are recommended especially in cases 
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with double expression of MYC and BCL2 and/or 
having a GCB phenotype and high-grade morphol-
ogy;
 – despite advanced diagnostic methods, still there 
is a group of cases whose image does not meet all 
criteria and “escapes” from diagnostic guidelines; 
the pathologist, taking into account the clinical 
presentation and course, should maximally narrow 
the differential diagnosis. It is worth remembering 
that the most powerful predictive factor determin-
ing the therapeutic approach remains the patho-
logically confirmed type of lymphoma; 
 – diagnosis of lymphomas requires close cooperation 
between haematopathologists and specialists in 
flow cytometry and genetics as well as clinicians 
(oncologists, haematologists).
Diffuse large B-cell lymphoma,  
not otherwise specified
Diffuse large B-cell lymphoma, not otherwise 
specified (DLBCL, NOS) is morphologically, clini-
cally and biologically heterogeneous. In developing 
countries and in selected Eastern European countries, 
such as Poland it represents 25-35% of non-Hod-
gkin’s lymphomas and is a constant leader among 
all aggressive mature B-cell lymphomas [3, 4]. The 
identification of two molecular subtypes of this lym-
phoma based on gene expression profiling (GEP) 
was one of the most important achievements in un-
derstanding its diversity. Subtyping DLBCL, NOS 
is based on different cell origins and includes lym-
phomas derived from germinal centre cells (GCB) or 
from activated B-cells (ABC) [5]. Additionally, these 
DLBCL subgroups vary in the activated molecular 
pathways, chromosomal changes, and the occurrence 
of somatic mutations. In GCB type, the activation 
of the PI3K/AKT signalling pathway and over-ex-
pression of BCL6 protein are observed, whereas in 
ABC type there is a constitutive activation of the 
NF-kB pathway in the course of various mecha-
nisms. Unique genetic changes, especially mutations 
such as GNA13 and EZH2 in GCB and MYD88, 
CARD11, and CD79B in ABC are found, respective-
ly [6, 7]. Chromosomal translocations in DLBCL in-
volving regions with BCL6 (3q27), BCL2 [t(14;18)
(q32;q21.3)], and MYC (single hit) comprise, re-
spectively, approximately 30% (with predominance 
in ABC subtype), 20-30% (more commonly in GCB 
subtype), and 8-14% (similar distribution among 
ABC and GCB subtype) [8, 9, 10, 11, 12, 13, 14, 
15, 16, 17, 18]. It is estimated that approximate-
ly 50% of DLBCL with MYC translocation demon-
strate BCL2 and/or BCL6 rearrangement and that 
cases should be transferred to the high-grade B-cell 
lymphoma category [1, 19, 20]. DLBCL with typ-
ical morphology and isolated MYC translocation 
usually present higher mitotic index, but still such 
cases meet the criteria of diagnosis of DLBCL, NOS 
[8, 21]. The pathologists are also discouraged from 
preselecting aggressive B-cell lymphomas to FISH 
testing upon Ki-67 result, while its range can be 
variable [21]. Biological differences translate into 
a distinct clinical course; so far in the majority of 
studies, a worse prognosis was observed among pa-
tients with DLBCL, ABC in comparison with GCB 
subtype. Moreover, the latest results of clinical tri-
als concerning combining R-CHOP regimen with 
bortezomib, lenalidomide, and ibrutinib in the ABC 
subtype significantly stress the potential benefits of 
such treatment [22, 23]. The optimal method for 
the molecular classification of DLBCL is the study 
of the gene expression profile, but it requires fresh 
tissue and is not widely used in routine diagnostics. 
Due to its clinical impact, pathologists are still ob-
ligated to precisely identify the molecular subtype. 
An up-to-date Hans algorithm based on a panel of 
antibodies (CD10, BCL6, and IRF4/MUM1) deter-
mined by immunohistochemistry is available in most 
pathology departments and should be continuous-
Fig. 1. EBV detection: A) immunohistochemical staining with LMP1 and B) EBER-ISH method (magnification 400×)
A B
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ly applied [24, 25, 26, 27]. The compliance of IHC 
with GEP reaches about 80-90%, but a small group 
of about 10% of DLBCL cases “slip out” of molec-
ular classification and the ABC/GCB match is not 
possible [28]. One of the limitations of IHC is also 
standardisation between haematopatholgy centres, 
including quality of staining and evaluation repro-
ducibility among pathologists [28, 29]. Recently 
developed GEP tests based on RNA extracted from 
formalin-fixed and paraffin-embedded tissues (e.g. 
the Lymph2Cx assay from NanoString Technologies, 
Seattle, WA, USA) can identify DLBCL molecular 
subtypes [30]. Moreover, those methods are charac-
terised by high compliance level with GEP microar-
rays and satisfactory reproducibility between labora-
tories [30, 31, 32]. Possibly, tests based on GEP will 
be a more precise diagnostic method than currently 
approved by the WHO IHC methods in future [1, 
20]. The summary of DLBCL, NOS characteristic is 
presented in Table II. 
High-grade B-cell lymphomas 
High-grade B-cell lymphoma (HGBL), with gene 
expression profile intermediate between molecular 
signatures of Burkitt lymphoma (BL) and non-BL 
(mostly DLBCL), is a heterogeneous group of aggres-
sive, mature B-cell lymphomas, which should not 
be classified separately due to biological and clini-
cal reasons [1, 2]. High-grade B-cell lymphoma is 
a newly introduced category in the updated 2017 
WHO classification, which primarily replaces B-cell 
lymphoma, unclassifiable, with features intermediate 
between diffuse large B-cell lymphoma and Burkitt 
lymphoma (BCLU, DLBCL/BL) and at the moment 
comprises two entities: HGBL with MYC and BCL2 
and/or BCL6 chromosomal rearrangements (HGBL, 
R) and high grade B-cell lymphomas, not otherwise 
specified (HGBL, NOS). HGBL, R is also called dou-
ble/triple-hit lymphoma (DH/THL). Most patients 
develop de novo HGBL, R, while a minority have 
a history of FL that progress to DH/THL secondari-
ly, presumably by acquisition of a MYC translocation 
[1]. Double/triple-hit lymphomas are characterised 
by various morphologies including DLBCL, BL and 
intermediate features between DLBCL and BL (DL-
BCL/BL). HGBL, which lack co-occurring MYC and 
BCL2 and/or BCL6 rearrangements, falling in the 
category HGBL, NOS; such cases appear as blastoid 
or DLBCL/BL morphology (eventually resembling 
more closely BL than DLBCL), and in up to half of 
DLBCL/BL cases MYC rearrangements as one sep-
arate hit are found [1, 2, 33, 34] (Fig. 2). Former 
criteria for BCLU, DLBCL/BL were vague, and the 
diagnosis was not used uniformly, limiting its utility 
as a diagnostic category [1, 2]. The morphological 
appearance should always be specified in a comment 
in the pathological report referring to HGBL, R 
and HGBL, NOS because the DLBCL morphology 
may predict a better outcome compared to DLB-
CL/BL [35]. Neither morphology nor proliferation 
index assessed by Ki-67 have sufficient sensitivi-
ty and specificity to identify DH/THLs. MYC and 
BCL2 protein expression, although independently 
valuable prognostic factors, are similarly not ideal 
predictors of DH/THLs, and hence FISH (whenev-
er the karyotype assessment is not available) is the 
recommended modality to identify DH/THLs (Fig. 
3) [1, 2]. Despite the fact that a clear consensus has 
not yet been reached to provide molecular testing 
guidelines, the 2017 WHO update strongly advises 
that all DLBCL cases should undergo genetic stud-
ies for the detection of MYC, BCL2, and BCL6 re-
arrangements. Nevertheless, some pathologists and 
clinicians suggest that only cases with a GCB phe-
notype and/or high-grade morphology or with > 
40% MYC immunohistochemically positive cells 
are worthy of deeper molecular testing [1] (Fig. 2). 
Nearly 100% of DHLs with MYC and BCL2 re-
arrangements harbour the t(14;18) translocation, 
which results in BCL2 overexpression by IHC and 
flow cytometry. BCL2 protein is expressed (in 30% 
of DHLs with MYC and BCL6 rearrangements) or 
overexpressed (occurrence of BCL2 extra copy/am-
plification) in a higher proportion of DLBCL and 
HGBL, NOS. That phenomenon is often associated 
with a concomitant expression of MYC, but still IHC 
evaluation cannot be used as a surrogate marker for 
DHL. Most DLBCL and HGBL do not carry both 
rearrangements (MYC and BCL2) and are referred to 
as “double-expressor lymphomas” (DELs) [1, 2, 33, 
36]. DH/THL and DEL patients usually progress 
more rapidly, are resistant to R-CHOP chemo-im-
munotherapy [33, 35], and have very poor prognosis. 
Moreover, such cases may harbour TP53 mutations 
or deletion, frequently observed in MYC/BCL2 DHLs 
and blastoid morphology [37, 38, 39]. Worse prog-
nosis in HGBL, R and HGBL, NOS compared with 
the DLBCL groups were published lately [38, 40]. 
DH/THLs show a common GCB immunophenotype 
(CD10+/CD81+higher/ BCL6+/CD44– or CD44+/–
dim) by FCM, often presenting decreased expression of 
CD20 or CD19, over expression of CD38 and BCL2 
(Fig. 4) [41]. An aggressive biologic behaviour and 
poor clinical outcome of DH/THL may shortly influ-
ence to therapy selection including still controversial 
more intensive regimens initiation and CNS-directed 
prophylaxis consideration. Under consideration is cy-
togenetic testing by metaphase or cytogenetic anal-
ysis by karyotyping if biological material (fresh cells 
from FNAB or tissue surgical section) is available. As 
far as possible, a comprehensive histopathological di-
agnostics of HGBL should include IHC, FISH, FCM 
and cytogenetic studies (Table III) [42, 43, 44]. 
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Burkitt Lymphoma and Burkitt-like 
lymphoma with 11q aberration 
Burkitt lymphoma (BL) is defined by the WHO 
classification as a highly aggressive lymphoid neo-
plasm, often presenting with extra nodal site in-
volvement or as an acute leukaemia composed of 
monomorphic, medium-sized B-cells with basophil-
ic cytoplasm and a high mitotic index. Translocation 
involving the MYC oncogene (8q24) and immuno-
globulin IG genes is the constant features in 90% of 
cases [1]. Case analysis without MYC rearrangement 
have shown at least several mechanisms for the alter-
native activation of MYC i.e. microRNA, amplifica-
tion, transcriptional increase of MYC activity. Results 
of next-generation sequencing revealed the BL pro-
file of somatic mutations; in about 70% of classic BL 
mutations of transcription factor TCF3 (E2A) and 
its negative regulator ID3 were found and its role in 
PI3K pathway signalling was observed. Furthermore 
CCND3, RHOA, TP53, ARID1A and SMARCA4 
mutations were identified in 30% of patients with BL. 
Recently, a subset of MYC translocation-negative 
aggressive B-cell lymphomas resembling BL, char-
acterized by proximal gains and distal losses of the 
long arm of chromosome 11 was described [45, 46]. 
In the 2017 WHO classification, these MYC-nega-
tive lymphomas were recognized as a new provision-
al entity, “Burkitt-like lymphoma with 11q aberra-
tion” (BLL,11q) [1] (Fig. 5). MYC-negative BLL,11q 
shows a number of clinico-pathological similarities to 
MYC-positive BL, but also harbour some significant 
differences in immunoprofile [1, 45, 46, 47, 48, 49, 
50]. BLL,11q usually express CD43/LMO2/CD56 
in IHC and CD16/CD56/CD38/CD45/CD8/CD43 
in FCM. That characteristics may contribute to the 
differential diagnosis of BLL, 11q and BL [49]. The 
11q aberrations in BLL, 11q (11q-gain/loss) were 
described as an inverted duplication of a part of the 
long arm of chromosome 11 with mono- or biallel-
ic telomeric deletion of 11q (Figure 6) [45, 46, 47, 
49]. Coincidence of duplication and deletion of 11q 
(11q23 and 11q24-qter, respectively) suggests a pos-
sibility of simultaneous up-regulation of oncogenes 
and down-regulation of tumour suppressor genes. 
The candidate oncogene is commonly up-regulated 
PAFAH1B2. FLI1 and ETS1, located in the region of 
deletion, are often down-regulated and/or mutated, 
and are postulated to be candidate tumour suppres-
sor genes affected by this aberration [46, 47]. The di-
agnostic algorithm for diagnosing BL and BLL, 11q, 
besides standard histopathological and immunohis-
tochemical examination, incorporates flow cytometry 
with a broad panel of monoclonal antibodies as well 
as genetic analysis (conventional cytogenetic analysis 
with fluorescence in situ hybridisation and molecular 
techniques) [1, 48]. Some cases with 11q aberration 
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also have MYC rearrangement and are diagnosed as 
BL or high-grade B-cell lymphoma, not otherwise 
specified (HGBL, NOS). From the other point of 
view, the 11q-gain/loss are not exclusively specific for 
BLL, 11q [47]. Therefore, the conventional cytoge-
netic analysis by metaphase karyotyping is needed to 
provide correct BLL, 11q diagnosis (Table IV) [49]. 
Other aggressive B-cell lymphomas
Changes in the WHO 2017 classification and di-
agnostic criteria of other aggressive lymphomas from 
mature B cells are less significant.
In the group of large B-cell lymphomas associated 
with infection with EBV the most common lympho-
ma is EBV-positive diffuse large B-cell lymphoma, 
not otherwise specified [DLBCL EBV(+), NOS]. 
In the previous WHO 2008 classification, this unit 
was called EBV-positive DLBCL of the elderly, due 
to significantly more frequent occurrence in patients 
over the age of 50 years with a peak of incidence in 
the eighth decade of life [51]. Recent studies have 
shown that these lymphomas may also occur in 
younger patients (mainly in the third decade of life 
and almost three times more often in men) [1, 20]. 
DLBCL EBV(+), NOS is characterised by a different 
clinical picture and pathological features comparing 
with DLBCL, NOS. Mainly it occurs in patients with 
immunological disorders that impair the control of 
viral infections. Histopathology reveals large atypical 
B cells that may resemble Hodgkin’s and Reed-Ster-
nberg cells, and variable inflammatory infiltrates in-
volving cytotoxic T lymphocytes [CD8(+)], plasmo-
cytes, and histiocytes. In addition, tumour necrosis 
is present in most cases. Histopathological features 
may suggest a diagnosis, but it should be confirmed 
by testing for the presence of EBV virus by in situ 
hybridisation, which is a superior method to IHC 
staining. EBV is found in most lymphoma cells and 
is usually in the second and third phase of latency 
[52]. Pictures of EBER-ISH and EBV-LMP1(IHC) 
are shown in Fig. 1.
In the group of large B-cell lymphomas classified on 
the basis of topography, the changes concern mainly 
primary mediastinal (thymic) large B-cell lymphoma 
(PMBL) and primary DLBCL of central nervous sys-
Fig. 2. Histopathology and immunohistochemistry of HGBL, R (A 400×; B, 600×; arrow); a case of a secondary 
triple-hit lymphoma (transformation from follicular lymphoma – arrowhead; HGBL, R – arrow) with DLBCL/BL mor-
phology. Immunohistochemical staining on HGBL, R cells: C – BCL2(+) weaker, D – MYC(+), E – CD38(+) higher, 
F – BCL6(+) weaker, G – MUM1(+), H – FOXP1(+) weaker, I – Ki-67 index (>90%) (for all IHC 400×)
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tem (DLBCL, CNS). PMBL cells frequently express 
PDL1/PDL2 markers (rearrangement in about 20% 
of cases), CD30 and CD23, and usually are negative 
for IG and HLA class I and II antigens [53]. Primary 
mediastinal lymphoma has a specific gene expression 
profile that can be useful in differential diagnosis of 
PMBL and DLBCL, NOS involving mediastinum or 
other outside thorax locations. Differences between 
PMBL and DLBCL at the molecular level relate to 
CIITA rearrangements (38% vs. rarely respective-
ly), which leads to the activation of NFkB and JAK/
STAT signalling pathways and the reduction of the 
antigen expression of the major histocompatibility 
complex of class II [5, 54, 55].
The primary DLBCL, CNS constitutes less than 
1% of non-Hodgkin’s lymphomas and approximate-
ly 2.4-3% of all brain tumours. It has separate bio-
logical features related to the immunologically priv-
ileged location in which it develops and the lack of 
expression of HLA class I and II proteins, which allow 
tumour cells to avoid immune control. It should be 
differentiated with other large cell lymphomas occur-
ring in the CNS, particularly with those associated 
with immunosuppression [56]; they are characterised 
with deletions and loss of gene expression within the 
HLA system and MYD88 L265P [> 50%], CD79B 
[20%], and CARD11 [16%] mutations are often ob-
served, which may have potential therapeutic signif-
icance [57, 58].
B-cell lymphomas with terminal B-cell differ-
entiation include a heterogeneous group of aggres-
sive lymphomas characterised by immunoblastic or 
plasmablastic cell morphology, a plasma cell pheno-
type with no or reduced expression of B-cell markers 
Fig. 3. A) Conventional cytogenetic diagnosis of double-hit lymphoma (DHL). Complex karyotype presenting DHL with 
diffuse large B-cell lymphoma morphology: 52,XX,+5,+7,t(8;14)(q24;q32),+der(12),t(6;12)(p11.2;p11.2) x2,t(14;18)
(q32;q21),+21,+mar, arrows indicate MYC, BCL2 and both IGH copies rearrangements. B) FISH with MYC break apart 
probe, split signal shows rearrangement of one copy of MYC gene in interphase nucleus. C) FISH with BCL2 break apart 
probe, split signal indicates rearrangement of one copy of BCL2 gene in interphase nucleus. D) FISH with IGH break 
apart probe, two split signals display rearrangement of two copies of IGH gene in interphase nucleus
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Fig. 4. Flow cytometry [FCM] of high grade B-cell lymphoma, triple hit [HGBL, TH]. A) FNAB/FCM analysis case with 
MYC/BCL2/BCL6 rearrangements. Forward scatter/side scatter picture showing the larger HGBL lymphoma cells (red 
cells) coexisting with of small normal T/B lymphocytes (green cells). HGBL express: CD45/ CD20+higher/ CD19+(C-
D20>CD19) / CD71+++/ CD81+higher / CD10+/ CD44+/−dim/ CD79β+higher / BCL6+ higher / MYC+ higher 
/ BCL2+ higher, and CD38+ higher [“higher” or “dim” means higher or more heterogeneous (from very weak to high) 
expression compared to expression on normal (green cells) B lymphocytes, respectively]. B) Higher level of BCL2 and 
CD38 expression (marked by an arrow) than in normal T/B lymphocytes correlates with BCL2 and MYC rearrangements, 
respectively. Dot-plots
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Fig. 5. Histopathological features of Burkitt-like lym-
phoma with 11q aberration (BLL,11q). Diffuse growth is 
composed of medium-sized lymphoid cells showing jigsaw 
puzzle effect of cytoplasmic borders with a starry pattern 
due to admixed macrophages (but in this case, you see a re-
duced phagocytosis and apoptotic bodies). The nuclei are 
similar in size and shape (HE, magnification 600×)
(CD20 and PAX5), and strong expression of plasma 
cell antigens (CD38, CD138, IRF4/MUM1, and 
PRDM1/BLIMP1) [1]. Highly aggressive plasmab-
lastic lymphoma (PBL) develops in immunocompro-
mised patients, mainly caused by HIV infection, as 
well as during iatrogenic immunosuppression (after 
transplantations, autoimmune diseases). It is usual-
ly located extranodally within the head and neck, 
including the oral cavity, also in the gastrointesti-
nal tract. In majority of cases the generalised disease 
stage is determined at the time of diagnosis (over 
75% of patients with HIV infection) [59, 60, 61]. 
In some cases, PBL involves bones and with its mor-
phological and immunophenotype features overlaps 
with plasmablastic plasma cell myeloma. The differ-
ential diagnosis should take into account the clini-
cal picture of PBL and immunodeficiency and EBV 
infection. The EBV virus in the first type of latency 
is present in about 70% of cases. MYC translocation 
occurs in about 50% of patients, usually with the IG 
partner [62]. 
Fig. 6. Conventional cytogenetic diagnosis of Burkitt-like lymphoma with 11q aberration (BLL,11q). A) A low complexi-
ty karyotype of BLL,11q: 45,X,-Y,del(6)(q21), dup(11)(q23q21), arrow indicates 11q gain/loss. B) FISH with centromere 
11 (Aqua) and KMT2A (break apart) probes, four red-green signals show multiplication of this region on duplicated chro-
mosome 11 (arrow). C) FISH with centromere 11 (Aqua) and ATM (locus specific, red) probes, two red signals indicate 
a duplication in 11q aberration region (arrow). D) FISH with centromere 11 (Aqua) and telomeric 11q (red) probes, one 
red 11q telomeric signal indicates normal chromosome 11, lack of red signal in 11q aberration confirms terminal deletion 
(arrow)
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In Table V pathological and immunohistochemi-
cal presentation of other aggressive B cell lymphomas 
were presented. 
Summary
In the diagnosis of aggressive B-cell lymphomas, 
parallel genetic tests should be done to determine the 
status of the MYC gene; these changes are complex 
and, although mostly involving classic translocations 
with one of the IG partners, also translocations with 
non-IG partners, mutations, transcriptional up-reg-
ulations, amplifications, and microRNA-dependent 
mechanisms are possible. This has a direct impact 
on the amount of protein product and its expression. 
BCL2 and BCL6 rearrangement and translocation 
mechanisms are well established. Two basic methods 
include the fluorescence in situ technique in break-
apart probe or dual-fusion; these are convenient and 
stable methods and can be used on formalin-fixed 
paraffin-embedded material. It makes these meth-
ods more available and allows the FFPE to be sent to 
a standardised FISH laboratory. FISH analysis can 
detect critical gene rearrangements or abnormalities 
in aggressive B-cell lymphomas. If fresh biopsy or 
tissue material is available karyotype analysis can 
reveal additional chromosome aberrations giving a 
more accurate picture of genetic changes clarifying 
the diagnosis.
In the comprehensive histopathological report, the 
following components should be determined:
 – cell morphology [blastoid, DLBCL, BL, DLBCL/
BL];
 – immunophenotype with reference to origin accord-
ing to Hans’s algorithm [GCB vs. non-GCB sub-
type];
 – MYC and BCL2 immunohistochemistry [double 
expressor vs. non-double expressor];
 – rearrangement of MYC, BCL2, BCL6 genes [pres-
ence or absence of MYC and BCL2 and/or BCL6 
rearrangements].
A summary of all diagnostic procedures in aggres-
sive B-cell lymphomas is shown in Fig. 7.
This work has been implemented using the Project infra-
structure POIG.02.03.00-14-111/13 funded by Opera-
tional Programme Innovative Economy 2007-2013, Pri-
ority II. R&D Infrastructure, Measure 2.3. Investments 
connected with development of IT infrastructure of Science.
The authors declare no conflict of interest.
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DLBCL BL DLBCL/BL Blastoid
CyclinD1
(–)
TdT
(–) (+)
B-LBLRearrangement MYC [FISH-BAP]
(–)
D-FISH: 
IGH/MYC, K/MYC, 
IGL/MYC #
Kariotype: 11q ##
(+)
Rearrangement BCL2 and/or BCL6 [FISH-BAP]
(–)
Morphology
DLBCL
Hans algorithm
IHC: BCL2 and MYC
GCB ABC
DE NDE
BL or DLBCL/BL
IHC: CD10, BCL6, MUM1IHC: CD10, BCL6, MUM1, BCL2, MYC
CD10(+),
BCL6(+),
MUM1(–),
BCL2(–),
MYC(+)
BL
Any other
phenotype
HGBL,
NOS
(+)
HGBL
/DH/TH
(+)
DLBCL or DLBCL/BL*
DLBCL
IHC: CD10, BCL6, MUM1
Hans algorithm
GCB
DE
ABC
NDE
IHC: BCL2 and MYC
(–) (–) (+)
BL Morphology BLlike
(+)
MCL
DLBCL – diffuse large B-cell lymphoma; BL – Burkitt lymphoma; MCL – cell lymphoma mantle; B-LBL – B-cell lymphoblastic leukaemia/lymphoma,  
HGBL,NOS – high-grade B-cell lymphoma, not otherwise specified; DH – double hit; TH – triple hit; DE – double expressor; NDE – not a double expressor; 
FISH-BAP – break-apart FISH probe; D-FISH – dual fusion FISH probe 
# additional evaluation, to be considered for the availability of the technique in correlation with the morphological image and clinical presentation 
## additional evaluation, to be considered for the availability of the technique in correlation with the morphological image and clinical presentation 
* morphology corresponding to small centroblasts or similar to lymphoblasts
Fig. 7. Diagnostic algorithm for aggressive B-cell lymphomas
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